Propionic Acid

Propionic Acid

SCHEMBL4896693

CCC(=O)[O-].CCC(=O)[O-].[K+].[K+]

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Propionic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 3/20 0.53
HDAC3 O15379 2/20 0.53
HDAC1 Q13547 2/20 0.53
HDAC2 Q92769 2/20 0.53
HDAC8 Q9BY41 2/20 0.53
CA4 P22748 5/20 0.47
TDP1 Q9NUW8 2/20 0.47
ALDH1A1 P00352 1/20 0.47
CA1 P00915 2/20 0.45
FAHD1 Q6P587 1/20 0.43
CASP1 P29466 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL29493216 1.00 FFAR3 (0.53) FFAR3HDAC3HDAC1HDAC2HDAC8
Propionic Acid SCHEMBL106190 1.00
Propionic Acid SCHEMBL21798886 0.96 FFAR3 (0.56) FFAR3HDAC3HDAC1HDAC2HDAC8
Propionic Acid SCHEMBL2070238 0.96
Propionic Acid SCHEMBL11050406 0.96 FFAR3 (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
Propionic Acid SCHEMBL11208525 0.96 FFAR3 (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
Propionic Acid SCHEMBL11214158 0.96
Propionic Acid SCHEMBL28884837 0.93
Oxalic Acid SCHEMBL6685439 0.93 FFAR3 (0.47) FFAR3HDAC3HDAC1HDAC2HDAC8
Propionic Acid SCHEMBL4813110 0.92 FFAR3 (0.53) FFAR3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4714958-A1 COMBINED THERAPY OF PHOTODYNAMIC THERAPY AND IMMUNE CHECKPOINT INHIBITOR Shanghai Guangsheng Biopharmaceutical Co., Ltd (CN) 2026-03-25 EP claimed
US-20260069696-A1 Combined therapy of photodynamic therapy and immune checkpoint inhibitor Shanghai Guang Sheng Pharmaceutical Co., Ltd. (CN) 2026-03-12 US claimed
WO-2025082342-A1 INTEGRATED PHOTODYNAMIC DIAGNOSIS AND TREATMENT METHOD 上海光声制药有限公司 2025-04-24 WO claimed
CN-119856902-A Photodynamic diagnosis and treatment integrated method 上海光声制药有限公司 2025-04-22 CN claimed
US-20250064743-A1 TREPROSTINIL DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS UNITED THERAPEUTICS CORPORATION (US) 2025-02-27 US claimed
WO-2024240023-A1 COMBINED THERAPY OF PHOTODYNAMIC THERAPY AND IMMUNE CHECKPOINT INHIBITOR 上海光声制药有限公司 2024-11-28 WO claimed
CN-119015410-A Combination therapy with photodynamic therapy and immune checkpoint inhibitors 上海光声制药有限公司 2024-11-26 CN claimed
US-20220280430-A1 TREPROSTINIL DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS UNITED THERAPEUTICS CORPORATION (US) 2022-09-08 US claimed
US-RE32416-E ACID PROPIONATE SALT IN BREAD BP CHEMICALS LIMITED (GB) 1987-05-12 US claimed
EP-0123416-A1 Method of producing solid potassium dipropionate VERDUGT B.V. (NL) 1984-10-31 EP claimed
EP-0112080-A1 Compound animal feedstuffs BP Chemicals Limited (GB) 1984-06-27 EP claimed
EP-0032807-B1 DIPOTASSIUM PENTAPROPIONATE AND METHOD OF PREPARING THE SAME BP Chemicals Limited (GB) 1983-01-19 EP claimed
EP-0032807-A1 Dipotassium pentapropionate and method of preparing the same BP Chemicals Limited (GB) 1981-07-29 EP claimed
US-4112122-A OF FOODS, METAL PROPIONATE BP CHEMICALS LIMITED (GB) 1978-09-05 US claimed
JP-59181236-A None JP disclosed
EP-4714958-A1 COMBINED THERAPY OF PHOTODYNAMIC THERAPY AND IMMUNE CHECKPOINT INHIBITOR Shanghai Guangsheng Biopharmaceutical Co., Ltd (CN) 2026-03-25 EP disclosed
US-20260069696-A1 Combined therapy of photodynamic therapy and immune checkpoint inhibitor Shanghai Guang Sheng Pharmaceutical Co., Ltd. (CN) 2026-03-12 US disclosed
EP-0032807-A1 Dipotassium pentapropionate and method of preparing the same BP Chemicals Limited (GB) 1981-07-29 EP disclosed
EP-0032807-A1 Dipotassium pentapropionate and method of preparing the same BP Chemicals Limited (GB) 1981-07-29 EP disclosed
US-4112122-A OF FOODS, METAL PROPIONATE BP CHEMICALS LIMITED (GB) 1978-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220280430-A1 TREPROSTINIL DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS TREH, TKT, TPP2 FFAR3 489/4885HDAC3 942/4885HDAC1 488/4885
US-20250064743-A1 TREPROSTINIL DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS TREH, THPO, TPP2 FFAR3 1177/4885HDAC3 981/4885HDAC1 833/4885
US-20260069696-A1 Combined therapy of photodynamic therapy and immune checkpoint inhibitor PDCD1, PDCD10, CD274 FFAR3 4651/4885HDAC3 1947/4885HDAC1 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.